









Markets
/
Stocks
/
nasdaq-acrv
/

Acrivon Therapeutics Inc

ACRV

2.010USD

-0.020-0.99%

Market hours （ET）Quotes delayed by 15 min

63.21MMarket Cap

LossP/E TTM



Acrivon Therapeutics Inc

2.010

-0.020-0.99%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Acrivon Therapeutics Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Acrivon Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

268 / 501

Overall Ranking

479 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

11.167

Target Price

+419.38%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Acrivon Therapeutics Inc Highlights

StrengthsRisks

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. The Company uses its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a potentially registrational Phase 2 trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore substantially improve the clinical overall response rate (ORR) and has the potential to enable expedited drug development. Its preclinical program, ACR-2316, is advancing in IND-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -0.93, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 17.85M shares, decreasing 16.32% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 509.30K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.47.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Acrivon Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.95, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -0.93, which is -48.04% below the recent high of -0.48 and -1650.00% above the recent low of -16.32.

Score

Industry at a Glance

Previous score

6.95

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 268/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.22, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Acrivon Therapeutics Inc is 10.50, with a high of 19.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.22

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

11.167

Target Price

+419.38%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Acrivon Therapeutics Inc

ACRV

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 4.34, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 2.26 and the support level at 1.80, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.36

Change

-0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.004

Buy

RSI(14)

54.340

Neutral

STOCH(KDJ)(9,3,3)

39.017

Sell

ATR(14)

0.174

High Vlolatility

CCI(14)

12.124

Neutral

Williams %R

65.152

Sell

TRIX(12,20)

0.749

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

2.088

Sell

MA10

2.047

Sell

MA20

1.964

Buy

MA50

1.752

Buy

MA100

1.528

Buy

MA200

2.390

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 56.75%, representing a quarter-over-quarter decrease of 24.39%. The largest institutional shareholder is The Vanguard, holding a total of 593.25K shares, representing 1.89% of shares outstanding, with 12.56% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

8.34M

Chione, Ltd.

3.85M

Blume-Jensen (Peter)

2.19M

-0.90%

Sands Capital Ventures LLC

2.12M

Citadel Advisors LLC

1.90M

Wellington Management Company, LLP

888.13K

The Vanguard Group, Inc.

Star Investors

593.25K

-12.08%

Renaissance Technologies LLC

Star Investors

509.30K

+877.53%

Acorn Capital Advisors, LLC

405.24K

Jacobs Levy Equity Management, Inc.

382.23K

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.